Tirzepatide use linked to lower mortality, improved cardiometabolic outcomes vs semaglutide in obese patients with hypothyroidism

Authors

• Andrew Cecil, Advocate Health - MidwestFollow

Recommended Citation

Cecil A. Tirzepatide use linked to lower mortality, improved cardiometabolic outcomes vs semaglutide in obese patients with hypothyroidism. Presentation at AACE 2026 Annual Meeting; April 23, 2026; Las Vegas, NV.

Affiliations

Advocate Aurora Health Care

Presentation Notes

Presentation at AACE 2026 Annual Meeting; April 23, 2026; Las Vegas, NV.

Media Mention Notes

Posted on Cleveland Clinical Journal of Medicine website

Type

Oral/Podium Presentation